Drug Trial Radar · NCT06948032
Study of BLU-808 in Healthy Adult Participants
Last checked: Nov 19, 2026Latest source record: Apr 28, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
95
Actual
Start
Aug 7, 2024
Primary completion
Jan 21, 2025
Study completion Jan 21, 2025
Sponsor
- Lead sponsor
- Blueprint Medicines CorporationIndustry
- Sponsor type
- Industry
- First posted
- Apr 28, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 19 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a 3-part study. Parts 1 and 2 are randomized, double-blind, placebo-controlled investigations of single ascending doses (SAD) (Part 1) and multiple ascending doses (MAD) (Part 2) of orally administered BLU-808 in healthy adult participants. Part 2 will also include an evaluation of the effect of multiple doses of BLU-808 on the single-dose pharmacokinetics (PK) of midazolam. Part 3 is an open-label, 2-sequence, 2-period, food effect (FE) study in healthy adult participants.
Conditions
- Healthy Participants
Interventions
BLU-808Drug
BLU-808 will be administered per schedule specified in the arm description.
PlaceboDrug
BLU-808 matching placebo will be administered per schedule specified in the arm description.
MidazolamDrug
Midazolam will be administered per schedule specified in the arm description.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1: Number of Participants With Treatment-emergent Adverse Events (TEAEs)Time frame: Up to Day 20
- Part 2: Number of Participants With TEAEsTime frame: Up to Day 50
- Part 3: Area Under the Plasma Concentration-time Curve From Time 0 to the Last Measurable Non-zero Concentration (AUC0-t)Time frame: Up to Day 6
- Part 3: Maximum Observed Plasma Concentration (Cmax)Time frame: Up to Day 6
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Celerion, Inc.
Lincoln, Nebraska
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.